Daiichi Sankyo Inc.Usage: ENHERTU treats HER2-positive and HER2-low/ultralow unresectable or metastatic breast cancer in adults, HER2-mutant non-small cell lung cancer, HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and HER2-positive (IHC 3+) unresectable or metastatic solid tumors with no satisfactory alternatives.